Vaccine

Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference

CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today…

3 years ago

Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases

-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif.,…

3 years ago

SteraMist to be Used in a Global Influenza Vaccine Facility in Australia

Company Continues To See Strong Bookings and A Robust Pipeline For Its Custom Engineered Systems in The Life Science SectorFREDERICK,…

3 years ago

Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A

– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent…

3 years ago

Bavarian Nordic Enters Agreement with Switzerland on the Supply of Smallpox and Monkeypox Vaccine

Switzerland has ordered 100,000 doses of smallpox and monkeypox vaccine with deliveries starting imminentlyBavarian Nordic will seek regulatory approval of…

3 years ago

Ramsay Sante : Annual results at the end of June 2022

PRESS RELEASE                 Paris, October 13th, 2022 Annual results at end June 2022 The solid performance of the Nordic countries has…

3 years ago

Altamira Therapeutics to Participate at RNA Leaders USA Congress

HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel…

3 years ago

GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above,…

3 years ago